Druggability & Clinical Context
Druggability
High
Score: 0.75
Target Class
Signaling Protein
Druggability Analysis
Structural Tractability0.70
Key Metrics
PDB Structures:
9
Known Drugs:
1
Approved:
0
In Clinical Trials:
0
Drug Pipeline (1 compounds)
1 Preclinical
Therapeutic Areas:Charcot-Marie-Tooth disease (CMT) Neurodegenerative diseases Lysosomal storage disorders Autophagy-related neurodegeneration Parkinson's disease Alzheimer's disease
Druggability Rationale: RAB7A is highly druggable (0.75 score) due to its GTPase catalytic activity, abundant structural data (9 PDB structures, 1.9 Å resolution), and proven precedent with preclinical RAB GTPase inhibitors like CID-1067700. The availability of both X-ray crystallography and cryo-EM structures, combined with well-characterized nucleotide-binding mechanisms, provides excellent opportunities for rational drug design targeting the GTP/GDP binding pocket.
Mechanism: RAB7A inhibitors or modulators would block or enhance GTPase-mediated late endosome and lysosome trafficking, disrupting autophagy flux and lysosomal degradation pathways. This can either impair pathogenic protein clearance (in certain cancers) or restore lysosomal function (in storage disorders and neurodegeneration).
Drug Pipeline (1 compounds)
1 Preclinical
Known Drugs:CID-1067700 (preclinical) — Rab GTPase inhibitor, endosomal trafficking modulator
Structural Data:PDB (9) ✓AlphaFold ✓Cryo-EM ✓
Binding Pocket Analysis:RAB7A contains a canonical GTPase nucleotide-binding pocket coordinating Mg2+ and GDP/GTP, with conserved switch regions (Switch I, II, III) that undergo conformational changes upon nucleotide exchange. Structural data suggests allosteric modulation opportunities through the C-terminal prenylation region and putative protein-protein interaction surfaces that may enable selective targeting without disrupting essential basal GTPase activity.
Selectivity & Safety Considerations
Selectivity against other RAB GTPases (>60 family members) is a primary challenge due to high sequence conservation in the GTP-binding domain; however, RAB7A-specific selectivity may be achievable through targeting divergent regions and regulatory protein-binding interfaces. Off-target effects on related endosomal RABs (RAB5, RAB9) require careful pharmacological profiling.